By Michael Erman CDC advisers narrow age recommendation for RSV shots in USJune 26 - A panel of outside experts to the U.S. CDC on Wednesday narrowed its recommendation for use of respiratory syncytial virus vaccines in older adults this year and held off on recommending their use for adults under age 60. Moderna received approval from the U.S. Food and Drug Administration for its shot, mRESVIA, for the same age group last month. The committee's work group said the balance of risk and benefits for the shot in that age group is more uncertain. Analysts, on average, expect sales of $1.59 billion for GSK's RSV shot, $1.47 billion for Pfizer's and $370 million this year for Moderna. In their clinical trials, GSK's RSV vaccine Arexvy was 78% effective in preventing severe RSV over a second year and Pfizer's Abrysvo was 78% effective through a second RSV season.

Source: Hindustan Times June 27, 2024 11:25 UTC